Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Dec 2, 2022
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-12-01$22.95/sh−865$19,852→ 6,629 total
Footnotes (1)
- [F1]Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person.